Jazz Pharmaceuticals (NASDAQ:JAZZ) Cut to Neutral at Cantor Fitzgerald
Cantor Fitzgerald cut shares of Jazz Pharmaceuticals (NASDAQ:JAZZ – Free Report) from an overweight rating to a neutral rating in a report published on Wednesday, Marketbeat Ratings reports. Cantor Fitzgerald currently has $150.00 price target on the specialty pharmaceutical company’s stock, up from their previous price target of $140.00. Several other brokerages have also recently […]
Cantor Fitzgerald cut shares of Jazz Pharmaceuticals (NASDAQ:JAZZ – Free Report) from an overweight rating to a neutral rating in a report published on Wednesday, Marketbeat Ratings reports. Cantor Fitzgerald currently has $150.00 price target on the specialty pharmaceutical company’s stock, up from their previous price target of $140.00. Several other brokerages have also recently […]
